Table 1. Clinical characteristics of patients with COVID-19 and laboratory results prior to administration of remdesivir.
| Characteristic | Patients with COVID-19 (n = 10) | ||
|---|---|---|---|
| Age, years | 52.0 (37.5 – 55.5) | ||
| Male sex (%) | 5 (50.0) | ||
| Smoking history, yes (%) | 3 (30.0) | ||
| Symptom, yes (%) | |||
| Cough | 5 (50.0) | ||
| Sputum | 2 (20.0) | ||
| Rhinorrhea | 1 (10.0) | ||
| Dyspnea | 2 (20.0) | ||
| Fever | 8 (80.0) | ||
| Fatigue | 1 (10.0) | ||
| Malaise | 0 (0.0) | ||
| Headache | 0 (0.0) | ||
| Gastrointestinal symptomsa | 1 (10.0) | ||
| Duration of illness, days | 4.00 (3.75 – 9.50) | ||
| Underlying respiratory disease, yes (%) | |||
| Chronic obstructive pulmonary disease | 0 (0.0) | ||
| Pulmonary tuberculosis, both active and inactive | 0 (0.0) | ||
| Asthma | 0 (0.0) | ||
| Other lung disease | 0 (0.0) | ||
| Other comorbidities, yes (%) | |||
| Hypertension | 3 (30.0) | ||
| Diabetes | 0 (0.0) | ||
| Cardiovascular disease (non-hypertensive) | 0 (0.0) | ||
| Cerebrovascular disease | 0 (0.0) | ||
| Autoimmune disease | 0 (0.0) | ||
| Peptic ulcer disease | 0 (0.0) | ||
| Chronic kidney disease | 0 (0.0) | ||
| Chronic liver disease | 1 (10.0) | ||
| Solid organ cancer | 0 (0.0) | ||
| Hematological malignancy | 0 (0.0) | ||
| Laboratory test | |||
| White blood cells (WBC), /mm3 | 4,750 (4,250 – 5,275) | ||
| Leukocytosisb, yes (%) | 0 (0.0) | ||
| Leukopeniac, yes (%) | 2 (20.0) | ||
| Platelets, × 103 cells/mm3 | 203 (172 – 219) | ||
| Platelets <150 × 103 cells/mm3, yes (%) | 0 (0.0) | ||
| Severe thrombocytopeniad, yes (%) | 0 (0.0) | ||
| AST, IU/L | 35 (22 – 43) | ||
| ALT, IU/L | 23 (15 – 36) | ||
| Total bilirubin, mg/dL | 0.43 (0.33 – 0.91) | ||
| Blood urea nitrogen, mg/dL | 10.5 (8.5 – 13.0) | ||
| Creatinine, mg/dL | 0.76 (0.61 – 0.93) | ||
| C-reactive protein, mg/L | 9.75 (2.73 – 32.80) | ||
| Lactate dehydrogenase, U/L | 281 (229 – 329) | ||
| Procalcitonin, ng/mL | 0.06 (0.05 – 0.13) | ||
Data are presented as the median (interquartile range) or as the number (percentage) unless otherwise indicated.
aGastrointestinal symptoms included nausea, vomiting, diarrhea, and abdominal pain.
bLeukocytosis was defined as a WBC count ≥10,000/mm3.
cLeukopenia was defined as a WBC count <4,000/mm3.
dSevere thrombocytopenia was defined as a platelet count <50,000 cells/mm3.
COVID-19, coronavirus disease 2019;AST, aspartate aminotransferase; ALT, alanine aminotransferase.